Age and genetic strain differences in response to chronic methylphenidate administration

Behavioural Brain Research

Volumn 218, Issue 1, 2011, Pages 206-217

  Yang, Pamela B ^b   Cuellar, Derly O ^a   Swann, Alan C ^a   Dafny, Nachum ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adolescent; Adult; Behavior; Genetic; Locomotor; Ritalin; Strain

Indexed keywords

METHYLPHENIDATE;

ADOLESCENT; ADULT ANIMAL; AGE; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR CHANGE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERANCE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; JUVENILE ANIMAL; LOCOMOTION; MALE; NERVE CELL NETWORK; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SPRAGUE DAWLEY RAT; STRAIN DIFFERENCE; WISTAR KYOTO RAT;

AGE FACTORS; ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; METHYLPHENIDATE; MOTOR ACTIVITY; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

EID: 78650605597     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.11.034     Document Type: Article

References (82)

1. Biederman J., Wilens T., Mick E., Spencer T., Faraone S.V. Pharmacotherapy of attention deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999, 1(4):e20.
2. Polanczyk G., de Lima M.S., Horta B.L., Biederman J., Rohde L.A. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007, 164:942-948.
3. Levin F.R., Kleber H.D. Attention-deficit hyperactivity disorder and substance abuse: relationships and implications for treatment. Harv Rev Psychiatry 1995, 2:246-258.
4. Solanto M.V. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998, 94:127-152.
5. Accardo P., Blondis T.A. What's all the fuss about Ritalin?. J Pediatr 2001, 138:6-9.
6. Rothenberger A., Danckaerts M., Dopfner M., Sergeant J., Steinhausen H.C. EINAQ -a European educational initiative on attention-deficit hyperactivity disorder and associated problems. Eur Child Adolesc Psychiatry 2004, 13(Suppl 1):I31-I35.
7. Huttenlocher P.R. Synaptic density in human frontal cortex - developmental changes and effects of aging. Brain Res 1979, 163:195-205.
8. Rakic P., Bourgeois J.P., Eckenhoff M.F., Zecevic N., Goldman-Rakic P.S. Concurrent overproduction of synapses in diverse regions of the primate cerebral cortex. Science 1986, 232:232-235.
9. Rosenberg D.R., Lewis D.A. Postnatal maturation of the dopaminergic innervation of monkey prefrontal and motor cortices: a tyrosine hydroxylase immunohistochemical analysis. J Comp Neurol 1995, 358:383-400.
10. Andersen S.L., Thompson A.T., Rutstein M., Hostetter J.C., Teicher M.H. Dopamine receptor pruning in prefrontal cortex during the periadolescent period in rats. Synapse 2000, 37:167-169.
11. Teicher M.H., Andersen S.L., Hostetter J.C. Evidence for dopamine receptor pruning between adolescence and adulthood in striatum but not nucleus accumbens. Brain Res Dev Brain Res 1995, 89:167-172.
12. Brandon C.L., Marinelli M., Baker L.K., White F.J. Enhanced reactivity and vulnerability to cocaine following methyl phenidate treatment in adolescent rats. Neuropsychopharmacology 2001, 25:651-661.
13. Laviola G., Wood R.D., Kuhn C., Francis R., Spear L.P. Cocaine sensitization in periadolescent and adult rats. J Pharmacol Exp Ther 1995, 275:345-357.
14. Bizot J.C., Chenault N., Houze B., Herpin A., David S., Pothion S., et al. Methylphenidate reduces impulsive r in juvenile Wistar rats, but not in adult Wistar, SHR and WKY rats. Psychopharmacology (Berl) 2007, 193:215-223.
15. Cailhol S., Mormede P. Strain and sex differences in the locomotor response and behavioral sensitization to cocaine in hyperactive rats. Brain Res 1999, 842:200-205.
16. Segal D.S., Kuczenski R. Individual differences in responsiveness to single and repeated amphetamine administration: behavioral characteristics and neurochemical correlates. J Pharmacol Exp Ther 1987, 242:917-926.
17. Post R.M., Weiss S.R., Pert A. Cocaine-induced behavioral sensitization and kindling: implications for the emergence of psychopathology and seizures. Ann NY Acad Sci 1988, 537:292-308.
18. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 1993, 18:247-291.
19. Russell V.A., de Villiers A.S., Sagvolden T., Lamm M.C., Taljaard J.J. Methylphenidate affects striatal dopamine differently in an animal model for attention-deficit/hyperactivity disorder-the spontaneously hypertensive rat. Brain Res Bull 2000, 53:187-192.
20. Yang P.B., Amini B., Swann A.C., Dafny N. Strain differences in the behavioral responses of male rats to chronically administered methylphenidate. Brain Res 2003, 971:139-152.
21. Yang P.B., Swann A.C., Dafny N. Acute and chronic methylphenidate dose-response assessment on three adolescent male rat strains. Brain Res Bull 2006, 71:301-310.
22. Roman T., Schmitz M., Polanczyk G., Eizirik M., Rohde L.A., Hutz M.H. Attention-deficit hyperactivity disorder: a study of association with both the dopamine transporter gene and the dopamine D4 receptor gene. Am J Med Genet 2001, 105:471-478.
23. Nigg J.T. Neuropsychologic theory and findings in attention-deficit/hyperactivity disorder: the state of the field and salient challenges for the coming decade. Biol Psychiatry 2005, 57:1424-1435.
24. Ruth J.A., Ullman E.A., Collins A.C. An analysis of cocaine effects on locomotor activities and heart rate in four inbred mouse strains. Pharmacol Biochem Behav 1988, 29:157-162.
25. Tolliver B.K., Belknap J.K., Woods W.E., Carney J.M. Genetic analysis of sensitization and tolerance to cocaine. J Pharmacol Exp Ther 1994, 270:1230-1238.
26. Elmer G.I., Gorelick D.A., Goldberg S.R., Rothman R.B. Acute sensitivity vs. context-specific sensitization to cocaine as a function of genotype. Pharmacol Biochem Behav 1996, 53:623-628.
27. Sagvolden T. Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit/hyperactivity disorder (AD/HD). Neurosci Biobehav Rev 2000, 24:31-39.
28. Russell V.A., Sagvolden T., Johansen E.B. Animal models of attention-deficit hyperactivity disorder. Behav Brain Funct 2005, 1:9.
29. Louis W.J., Howes L.G. Genealogy of the spontaneously hypertensive rat and Wistar-Kyoto rat strains: implications for studies of inherited hypertension. J Cardiovasc Pharmacol 1990, 16(Suppl 7):S1-S5.
30. Johnson M.L., Ely D.L., Turner M.E. Genetic divergence between the Wistar-Kyoto rat and the spontaneously hypertensive rat. Hypertension 1992, 19:425-427.
31. Gaytan O., al-Rahim S., Swann A., Dafny N. Sensitization to locomotor effects of methylphenidate in the rat. Life Sci 1997, 61:PL101-PL107.
32. Crawford C.A., McDougall S.A., Meier T.L., Collins R.L., Watson J.B. Repeated methylphenidate treatment induces behavioral sensitization and decreases protein kinase A and dopamine-stimulated adenylyl cyclase activity in the dorsal striatum. Psychopharmacology (Berl) 1998, 136:34-43.
33. Yang P., Beasley A., Swann A., Dafny N. Valproate modulates the expression of methylphenidate (ritalin) sensitization. Brain Res 2000, 874:216-220.
34. Kuczenski R., Segal D.S. Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine. J Pharmacol Exp Ther 2001, 296:876-883.
35. Lee M.J., Swann A.C., Dafny N. Methylphenidate sensitization is prevented by prefrontal cortex lesion. Brain Res Bull 2008, 76:131-140.
36. Algahim M.F., Yang P.B., Wilcox V.T., Burau K.D., Swann A.C., Dafny N. Prolonged methylphenidate treatment alters the behavioral diurnal activity pattern of adult male Sprague-Dawley rats. Pharmacol Biochem Behav 2009, 92:93-99.
37. Gaytan O., Yang P., Swann A., Dafny N. Diurnal differences in sensitization to methylphenidate. Brain Res 2000, 864:24-39.
38. Yang P.B., Swann A.C., Dafny N. Chronic administration of methylphenidate produces neurophysiological and behavioral sensitization. Brain Res 2007, 1145:66-80.
39. Barron E., Yang P.B., Swann A.C., Dafny N. Adolescent and adult male spontaneous hyperactive rats (SHR) respond differently to acute and chronic methylphenidate (Ritalin). Int J Neurosci 2009, 119:40-58.
40. Dougherty P.M., Dong W.Q., Faillace L.A., Dafny N. Trans-cranial electrical stimulation attenuates abrupt morphine withdrawal in rats assayed by remote computerized quantification of multiple motor behavior indices. Eur J Pharmacol 1990, 175:187-195.
41. Gaytan O., Swann A., Dafny N. Diurnal differences in rat's motor response to amphetamine. Eur J Pharmacol 1998, 345:119-128.
42. Yang P., Singhal N., Modi G., Swann A., Dafny N. Effects of lithium chloride on induction and expression of methylphenidate sensitization. Eur J Pharmacol 2001, 426:65-72.
43. Andersen E., Dafny N. Dorsal raphe nucleus modulates sensory evoked responses in caudate and septum. Int J Neurosci 1982, 17:151-155.
44. Andersen E., Dafny N. Dorsal raphe stimulation reduces responses of parafascicular neurons to noxious stimulation. Pain 1983, 15:323-331.
45. Reyes-Vazquez C., Dafny N. Does naloxone have functional significant activity on medial thalamic neurons? Microiontophoretical study. Life Sci 1983, 32:1443-1448.
46. Volkow N.D., Wang G.J., Fowler J.S., Fischman M., Foltin R., Abumrad N.N., et al. Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci 1999, 65:PL7-PL12.
47. Teo S.K., Stirling D.I., Thomas S.D., Khetani V.D. Neurobehavioral effects of racemic threomethylphenidate and its d and l enantiomers in rats. Pharmacol Biochem Behav 2003, 74:747-754.
48. Pierce R.C., Kalivas P.W. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev 1997, 25:192-216.
49. Kalivas P.W. Interactions between dopamine and excitatory amino acids in behavioral sensitization to psychostimulants. Drug Alcohol Depend 1995, 37:95-100.
50. Wolf M.E. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol 1998, 54:679-720.
51. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 1986, 396:157-198.
52. Gessa G.L., Pani L., Serra G., Fratta W. Animal models of mania. Adv Biochem Psychopharmacol 1995, 49:43-66.
53. Lieberman J.A., Sheitman B.B., Kinon B.J. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 1997, 17:205-229.
54. Phillips T.J. Behavior genetics of drug sensitization. Crit Rev Neurobiol 1997, 11:21-33.
55. White S.R., Yadao C.M. Characterization of methylphenidate exposures reported to a regional poison control center. Arch Pediatr Adolesc Med 2000, 154:1199-1203.
56. Gatley S.J., Volkow N.D., Gifford A.N., Fowler J.S., Dewey S.L., Ding Y.S., et al. Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans. Psychopharmacology (Berl) 1999, 146:93-100.
57. Gainetdinov R.R., Jones S.R., Fumagalli F., Wightman R.M., Caron M.G. Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Res Brain Res Rev 1998, 26:148-153.
58. Gerasimov M.R., Franceschi M., Volkow N.D., Gifford A., Gatley S.J., Marsteller D., et al. Comparison between intraperitoneal and oral methylphenidate administration: a microdialysis and locomotor activity study. J Pharmacol Exp Ther 2000, 295:51-57.
59. Sagvolden T., Sergeant J.A. Attention deficit/hyperactivity disorder-from brain dysfunctions to behavior. Behav Brain Res 1998, 94:1-10.
60. Swanson J., Gupta S., Guinta D., Flynn D., Agler D., Lerner M., et al. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther 1999, 66:295-305.
61. Solanto M.V. Clinical psychopharmacology of AD/HD: implications for animal models. Neurosci Biobehav Rev 2000, 24:27-30.
62. Kollins S.H., MacDonald E.K., Rush C.R. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav 2001, 68:611-627.
63. Spear L.P., Brake S.C. Periadolescence: age-dependent behavior and psychopharmacological responsivity in rats. Dev Psychobiol 1983, 16:83-109.
64. Froimowitz M., Patrick K.S., Cody V. Conformational analysis of methylphenidate and its structural relationship to other dopamine reuptake blockers such as CFT. Pharm Res 1995, 12:1430-1434.
65. Gatley S.J., Pan D., Chen R., Chaturvedi G., Ding Y.S. Affinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters. Life Sci 1996, 58:231-239.
66. Kuczenski R., Segal D.S. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 1997, 68:2032-2037.
67. Challman T.D., Lipsky J.J. Methylphenidate: its pharmacology and uses. Mayo Clin Proc 2000, 75:711-721.
68. Volkow N.D., Wang G., Fowler J.S., Logan J., Gerasimov M., Maynard L., et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001, 21:RC121.
69. Leonard B.E., McCartan D., White J., King D.J. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol 2004, 19:151-180.
70. Smith G.P., Schneider L.H. Relationships between mesolimbic dopamine function and eating behavior. Ann NY Acad Sci 1988, 537:254-261.
71. Tejani-Butt S.M., Pare W.P., Yang J. Effect of repeated novel stressors on depressive behavior and brain norepinephrine receptor system in Sprague-Dawley and Wistar-Kyoto (WKY) rats. Brain Res 1994, 649:27-35.
72. Pare W.P., Tejani-Butt S.M. Effect of stress on the behavior and 5-HT system in Sprague-Dawley and Wistar-Kyoto rat strains. Integr Physiol Behav Sci 1996, 31:112-121.
73. Jiao X., Pare W.P., Tejani-Butt S. Strain differences in the distribution of dopamine transporter sites in rat brain. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:913-919.
74. Russell V., de Villiers A., Sagvolden T., Lamm M., Taljaard J. Altered dopaminergic function in the prefrontal cortex, nucleus accumbens and caudate-putamen of an animal model of attention-deficit hyperactivity disorder-the spontaneously hypertensive rat. Brain Res 1995, 676:343-351.
75. Linthorst A.C., Van den Buuse M., De Jong W., Versteeg D.H. Electrically stimulated [3H]dopamine and [14C]acetylcholine release from nucleus caudatus slices: differences between spontaneously hypertensive rats and Wistar-Kyoto rats. Brain Res 1990, 509:266-272.
76. Bolanos C.A., Glatt S.J., Jackson D. Subsensitivity to dopaminergic drugs in periadolescent rats: a behavioral and neurochemical analysis. Brain Res Dev Brain Res 1998, 111:25-33.
77. Grund T., Lehmann K., Bock N., Rothenberger A., Teuchert-Noodt G. Influence of methylphenidate on brain development--an update of recent animal experiments. Behav Brain Funct 2006, 2:2.
78. Kalsbeek A., Voorn P., Buijs R.M., Pool C.W., Uylings H.B. (Development of the dopaminergic innervation in the prefrontal cortex of the rat. J Comp Neurol 1988, 269:58-72.
79. Dawirs R.R., Teuchert-Noodt G., Czaniera R. Maturation of the dopamine innervation during postnatal development of the prefrontal cortex in gerbils (Meriones unguiculatus). A quantitative immunocytochemical study. J Hirnforsch 1993, 34:281-290.
80. Moll G.H., Hause S., Ruther E., Rothenberger A., Huether G. Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters. J Child Adolesc Psychopharmacol 2001, 11:15-24.
81. Fone K.C., Nutt D.J. Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol 2005, 5:87-93.
82. Mathews I.Z., McCormick C.M. Female and male rats in late adolescence differ from adults in amphetamine-induced locomotor activity, but not in conditioned place preference for amphetamine. Behav Pharmacol 2007, 18:641-650.